1DPRE-DRI

InsermInsermFrench National Institute of Health

andMedical Research

• Created in 1964 from the National Institute of Hygiene and Hospital Research

•Working through the Ministries for Research and Health

2DPRE-DRI

Inserm : key figures

Budget 2006 : 700 M€Total staff: 13 000

(2 500 physicians) of which 5 100 Inserm employees

(62% of total budget dedicated to salaries)

335 Inserm laboratories19 research centers

374 French and foreign firms are partners of Inserm

An active patent portfolio of 572 families

41 Clinical Investigation Centers (CIC)

56 start-up companies based on Inserm technology

4DPRE-DRI

13DPRE-DRI

18DPRE-DRI

• Inter-research agencies programmes :- CNRS : SPI, STIC, chemistry, etc..- INRIA

• Dedicated research units in specific infrastructures:

ex: CNG, Nanotechnology

• Dedicated research Programmes :- Nanotechnology- « Systems biology »

• Training

« Interdisciplinarity »

19DPRE-DRI

Inserm : creation of research centers

Objectives and main characteristics:• Critical mass (100 to 300 staffs),• Mutualisation and Integration• International visibility, Attractiveness

Assessment criteria:• Scientific excellence• Quality of the management :

Governing structure, mutualised administration & managementTechnology transfert and research outcomes

Sharing of technical facitiliesCoordination of scientific events and programmesImplementation of research training programmesInternational scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)

20DPRE-DRI

19 Centres de Recherche au 1/07/2007

22DPRE-DRI

Evolution des unités et CDR entre 2001 et 2007

23DPRE-DRI

Infrastructures de recherche

CNRG: CNS, CNG, RNG

R.I.O: Inserm, CNRS, CEA, INRA

(Universités, Hôpitaux)

IFRRégions

UnitésDe

recherche

EUROPE7e PCRDT

ESFRI

« Grosses » infrastructures: P4 (Lyon) ICS (Strasbourg) Mircen (Fontenay: CEA-Inserm)

25DPRE-DRI

Regional clustersRegional clusters

1.1. CanceropolesCanceropoles, , other thematic poles other thematic poles (Neuropole, …)(Neuropole, …)

2.2. CompetitivityCompetitivity clusters clusters (Industry)

3.3. Regional poles for research in Regional poles for research in

Neurosciences, etc.Neurosciences, etc.

26DPRE-DRI

Competitivity Clusters

67 created clusters 7 involving Inserm units

International

National

Emergent

Virology

Nutrition, Ageing

Imaging, Cancer, Biotherapies, Neurosciences

Biotherapies

Cancer, therapeutics

Therapeutic innovation

Nutrition

28DPRE-DRI

Main Inserm’s priorities

1. « Researchers » : Careers, Training & Mobility

2. To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach

3. To establish Inserm in a European and International context

4. To develop public/private partnerships

31DPRE-DRI

Le recrutement chercheur

• Contrats jeunes chercheurs « Juniors »: 5 ans (évaluation intermédiaire à 3 ans) 30%: Avenir Suivi: mission chercheurs

• Chargés et Directeurs de recherche

• Contrats post-doctorants 12 mois (24 mois ?) (Postes verts)

32DPRE-DRI

Post-doctoral career track Inserm-NIH (appel d’offres permanent)

• Candidats proposés par l’Inserm après leur thèse: 3 ans de post-doctorat dans l’un des instituts des NIH « intra-muros ».

• Suivi personalisé (mission chercheurs), évaluation de la qualité du stage post-doctoral

• Contrat Junior (5ans, avec évaluation à 3 ans) Contrat temporaire universitaire ou HU

• Recrutement: EPST, Université etc ..

33DPRE-DRI

Contrats d’interface pour chercheurs et ingénieurs de recherche

CRDRIR

HôpitalCHU, CLCC

383

Internationaux(Labos internationaux)

2

Agences SanitairesN: 5

Inserm (ISFIC)Chercheurs: 50Ingénieurs: 37

Université60

Industrie6

34DPRE-DRI

Contrats d’Interface Médecins hospitaliers et HU et Enseignants-

chercheurs

HOPITALINSERM

88 PH, MCU-PH,PU-PH

UNIVERSITEINSERM

11 enseignants-chercheurs

48DPRE-DRI

BasicResearch

Preclinical studies : Proof of concept

Inserm Inserm

[CRC]

Inserm

Phases IIb-III

Phase IVCohorts

Clinical trialsClinical trials

Proof of conceptPhases I-IIaBiotherapy

52DPRE-DRI

2006 < 2000 2000 2001 2002 2003 2004 2005

CIC CIC-ECCIC Biothérapie

23 7

11

41

10 10 17 21

21

+

7

24

+

7

24

+

17

Collections biologiques 47 - - 16 30 47 47 47

Cohortes 147 99 117 131 135 142 147 147

Registres - - 17 29 29 31 35

Réseaux 26 - - 9 22 22 22 26

Infrastructures de recherche cliniqueEt en santé des populations

Infrastructures de recherche cliniqueEt en santé des populations

35

53DPRE-DRI

Les CIC

• CIC « généralistes »

• CIC-EC: épidémiologie et gestion des essais cliniques

• CIC-Biothérapie

• 2007: CIC-»innovations technologiques »

54DPRE-DRI

CIC et Unités Inserm

• Promotions Inserm: 20% demandées par les CIC

• Etudes et essais cliniques réalisées dans les CIC: environ 20-30% viennent des unités

55DPRE-DRI

CIC

Services de soins et de biologie

CHU

Postes d’accueil pour internes

Contrats chercheurs Juniors 5 ans

Contrats d’interface

Unités de rechercheInserm

Equipes de rechercheTranslationnelle

Budget de base + projets

Comment renforcer les collaborations?

59DPRE-DRI

Pan-European network of Clinical research infrastructures: the ECRIN network of INSERM

ECRIN : European Clinical Research Infrastructures Network

FranceFranceCIC & UECCIC & UEC

SpainSCReN

ItalyCIRM & IRFMN

GermanyKKS

DenmarkDCRIN

SwedenSweCRIN

QuébecFRSQ-GEREQ

Other networks

National networks of Clinical Research

Centres Clinical Trial Units

EFGCP

ECRIN should be considered as a tool that will allow:- to access research facilities certified as compliant with the GMP/GLP standards in Europe- to access expertise in the preparation and conduct of trans-national clinical trials - to access scientific and ethic evaluations

72DPRE-DRI

National Research Programmes

Main missions of the Inserm National Research Programmes :

• To support new/young research teams• To support organisation of seminars and workshops : prospective

studies and follow-up of actions• To identify projects that could be submitted to FP7 or some other

international programmes (NIH, etc• Collaborations with the NIH: seminars and grants• To reinforce partnerships with

Patients associations

Medical specialised scientific societies

Industry

73DPRE-DRI

National Research Programmes

National Research Program on Cardiovacular Diseases PNRC

National Research Program on Diabetes PNRDin collaboration with CNRS

National Research Program on Human Nutrition PRNHin collaboration with INRA

National Research Program on Bone and Joint Diseases PRO-A

Virtual Institute for Public Health Research IVRSP

National Research Program on sense organs PNRV

79DPRE-DRI

The European and International cooperations

81DPRE-DRI

The main axes

EU Prospectives (ESF, EUROHORCS, etc.)

Participation in European programmes : RTD FP & Public Health FP

Infrastructures - ESFRI (ECRIN, …)

Researchers’ mobility within EU programmes and

Bilateral actions: Common Research projects -Associated laboratories - Joint-units abroad

84DPRE-DRI

Inserm-Transfert SA

• Private subsidiary of the French National Institute for Health and Medical Research (Inserm)

• Created by Inserm in 2001, funded up to 4,5 M€ by Inserm and comprising actually 50 people

• Increase researchers’ awareness of technology transfer and company creation

• Identification and promotion of innovative projects emerging from Inserm’s laboratories

• Launch of a new seed fund called “Inserm-Transfert Initiative” with three major investors in the biotech field (Sofinnova, Ventech, CDC Entreprise) - Capital amount = 4.2 M€

85DPRE-DRI

International project management

21 projects under management (6 Network of Excellence, 3 Integrated Projects, 12 STREP) and 8 projects under negociation

Total budget for all projects under management over 200 million €

Creation of value by up-coming licensing and SME’s participation

Inserm-Transfert has invested 800 kEuros in 11 new biotech companies that have raised 85 million euros

600 patents' family - 60 to 90 New demands/year - 480 licensing agreements

Biotech start-up creation and Patenting

86DPRE-DRI

Bilateral cooperations’ actions

Researchers' mobility (short-medium term, Interface Contract grants)

Research networks ( EU programmes , NIH, Bill Gates etc..)

Associated laboratories

Joint Research unit abroad

92DPRE-DRI

Associated Laboratory

Inserm Unit Abroad

Scientific driven

2x4 years mandate

Synergies: competencies and facility access

Co-funding by Inserm and Associated partners

Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)

Networks, EU research projects

Bilateral cooperations’ tools

94DPRE-DRI

Bruxelles

Heidelberg

Glasgow

Rome

Milan

Prague

European Associated laboratory (LEA)

Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles)

Lille : M. Capron U547 / Bruxelles : M. Goldman (IMI)

Associated laboratories

(under preparation)

Milan / Bordeaux

Rome / Villejuif

Rome / Nice

Ferrara / Paris

Dundee / Toulouse

Freiburg / Strasbourg

Berlin / Paris

Barcelona / Paris

Porto / Toulouse

Joint Research Unit in Europe:

Université de Glasgow / C. Doerig U609

DKFZ / J. Rommelaere U701

Dundee

Ferrara

Berlin Freiburg

Barcelona

Porto

96DPRE-DRI

Montréal

Pittsburgh

Rio de Janeiro

INSERM UnitAssociated LaboratoryIn preparation

Irvine

Montreal

Shanghai

Tokyo

Kyoto

SeoulNew York

NanjingDallas

BeijingHaïfa

Doha

Los Angeles

Buenos Aires

Laval

WuhanRabat

Guangzhou

Singapour

97DPRE-DRI

« European and International Interface Contract » grants ?

Pilot action under preparation

Permanent position by Inserm + temporary contract: “2/3 base salary + 1/3 supplementation” 

112DPRE-DRI« Le concert », Nicolas de Staël, 1955